The AbTCR fuses an antigen-binding domain from anti-CD22 (Inotuzumab) antibody with the C- terminal signaling domain of a γδTCR. More specifically, the antigen-binding domain of our AbTCR is an antibody Fab fragment, and the cellular-activation domain of consists of portions of the δ and γ chains of a γδTCR. And the vector product is designed to facilitate T-cell cytotoxicity with low cytokine release and is used in Acute lymphoblastic leukemia (ALL).
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Call us at:
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE